Pharma Choice LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Pharma Choice LLP Pharmaceutical Export Portfolio Dataset — 4 Products, $384.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pharma Choice LLP — Pharmaceutical Exporter Profile (2026) | 4 Products, $384.5K Trade | TransData Nexus

Pharma Choice LLP

Indian Pharmaceutical Exporter · Other Specialist · $384.5K Total Trade · DGFT Verified

Pharma Choice LLP is an Indian pharmaceutical exporter with a total trade value of $384.5K across 4 products in 3 therapeutic categories. Based on 80 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Serum ($306.2K), Lenvatinib ($29.2K), Adalimumab ($26.7K).

Pharma Choice LLP — Export Portfolio & Destination Treemap

Pharma Choice LLP pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Pharma Choice LLP? — Company Overview & Market Position

Pharma Choice LLP is a pharmaceutical exporter based in Mumbai, Maharashtra, India. Established on September 15, 2017, the company operates as a Limited Liability Partnership (LLP) under the registration number AAK-5983. The registered office is located at Shop No. 12, Ground Floor, Sairam Apartment, Mulund Sai CHS Ltd, Mhada Colony, Mulund East, Mumbai, Maharashtra, 400081, India.

The ownership structure comprises three designated partners: Ganesh Rangnath Sanap, Mangesh Rangnath Sanap, and Akshay Rao Harishchandra, all appointed on September 15, 2017. The company has a total obligation of contribution amounting to ₹600,000. As of the latest available data, Pharma Choice LLP has an annual turnover ranging between ₹2 to ₹5 crore (approximately $400,000 to $1 million). The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

What Does Pharma Choice LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Serum$306.2K 2

Product Portfolio — Top 4 by Export Value

Pharma Choice LLP exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Serum	Other	$306.2K	26	1.1%	12
2	Lenvatinib	Advanced Oncology	$29.2K	23	1.4%	9
3	Adalimumab	Biologics & Immunotherapy	$26.7K	23	2.2%	4
4	Antitoxin	Other	$22.5K	8	0.2%	14

Pharma Choice LLP exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $384.5K. The top category is Other (85.5% of portfolio), followed by Advanced Oncology (7.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Pharma Choice LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Pharma Choice LLP operates manufacturing facilities in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the manufacturing capacities and specializations are not publicly disclosed. The facilities are designed to adhere to international quality standards, ensuring the production of high-quality pharmaceutical products for export markets.

3Key Leadership

The leadership team of Pharma Choice LLP comprises three designated partners:

Ganesh Rangnath Sanap: Designated Partner since September 15, 2017.
Mangesh Rangnath Sanap: Designated Partner since September 15, 2017.
Akshay Rao Harishchandra: Designated Partner since September 15, 2017.

These individuals collectively oversee the strategic direction and operations of the company, leveraging their expertise to drive growth and maintain compliance with regulatory standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Pharma Choice LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Pharma Choice LLP's export activities are primarily focused on markets in Asia, including the Philippines. The company has engaged in the export of pharmaceutical products such as the Hepatitis B Vaccine rDNA 100mcg to the Philippines, indicating a presence in the Southeast Asian market. Specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's export strategy appears to be concentrated in select Asian markets, with limited information on its presence in other regulated markets.

2Emerging Markets

Pharma Choice LLP has demonstrated a presence in emerging markets, particularly in Southeast Asia. The export of the Hepatitis B Vaccine rDNA 100mcg to the Philippines suggests an engagement with the Southeast Asian pharmaceutical market. However, specific information regarding the company's activities in Africa, Latin America, and other parts of Southeast Asia is not publicly available. The company's focus on select markets indicates a strategic approach to market penetration, potentially leveraging WHO prequalification to enhance access in these regions.

3Geographic Strategy

Pharma Choice LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Pharma Choice LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities appear to be primarily focused on markets in Asia, with limited information on its presence in the United States. This suggests that Pharma Choice LLP may not currently have FDA approvals or registrations for its products.

2WHO & EU GMP

There is no publicly available information indicating that Pharma Choice LLP holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The company's export activities are primarily focused on select Asian markets, and it is unclear whether its manufacturing facilities comply with WHO or EU GMP standards. Obtaining such certifications could enhance the company's credibility and facilitate access to additional international markets.

3CDSCO & Indian Regulatory

Pharma Choice LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. Specific details regarding the company's manufacturing licenses, approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly available. The company's focus on select export markets suggests compliance with Indian regulatory requirements for pharmaceutical exports.

Pharma Choice LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Pharma Choice LLP operates in a competitive landscape with numerous pharmaceutical exporters in India. While specific competitors in overlapping categories are not publicly identified, the company's focus on select Asian markets suggests competition with other exporters targeting similar regions. The company's market share in these regions is not publicly disclosed, making a direct head-to-head analysis challenging.

2Key Differentiators

Pharma Choice LLP's key differentiators include its specialization in finished pharmaceutical formulations and its focus on select Asian markets. The company's product portfolio, as indicated by its export data, includes a range of pharmaceutical products across various therapeutic categories. However, specific details regarding the uniqueness of its product offerings are not publicly available.

3Strategic Position

Pharma Choice LLP's current strategic direction appears to be focused on exporting finished pharmaceutical formulations to select Asian markets. The company's limited geographic diversification suggests a targeted approach to market penetration. Future strategic directions may involve expanding its product portfolio, obtaining international certifications such as WHO prequalification and EU GMP, and exploring additional export markets to enhance growth prospects.

Buyer Due Diligence Brief — Evaluating Pharma Choice LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Pharma Choice LLP's track record in exporting pharmaceutical products is evident from its export data, which includes shipments of products like the Hepatitis B Vaccine rDNA 100mcg to the Philippines. The company's export volume and consistency are not publicly disclosed, making a comprehensive assessment of its reliability challenging. However, the company's focus on select markets suggests a strategic approach to supply chain management.

2Certifications to Verify

Importers should verify the following certifications when considering Pharma Choice LLP as a supplier:

FDA Registration: To confirm compliance with U.S. regulatory standards. Verification can be done through the FDA's official website.
WHO-GMP Certification: To ensure adherence to international manufacturing standards. Verification can be done through the WHO's official website.
EU GMP Certification: To confirm compliance with European manufacturing standards. Verification can be done through the European Medicines Agency's official website.

Frequently Asked Questions — Pharma Choice LLP

How many pharmaceutical products does Pharma Choice LLP export from India?

Pharma Choice LLP exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Serum ($306.2K), Lenvatinib ($29.2K), Adalimumab ($26.7K), Antitoxin ($22.5K). Total export value is $384.5K.

What is Pharma Choice LLP's total pharmaceutical export value?

Pharma Choice LLP's total pharmaceutical export value is $384.5K, based on 80 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Pharma Choice LLP cover?

Pharma Choice LLP exports across 3 therapeutic categories. The largest are Other (85.5%, 2 products), Advanced Oncology (7.6%, 1 products), Biologics & Immunotherapy (6.9%, 1 products).

Get Full Pharma Choice LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.